SEC Comment Letter for NRX Pharmaceuticals, (NRXP) — Jun 24, 2025
NRX Pharmaceuticals, Inc.
Date: June 24, 2025 · CIK: 0001719406 · Accession: 0000000000-25-006576
AI Filing Summary & Sentiment
File numbers found in text: 333-288205
Letter
June 24, 2025 Jonathan Javitt Chairman and Interim Chief Executive Officer NRX Pharmaceuticals, Inc. 1201 Orange Street, Suite 600 Wilmington, DE 19801 Re:NRX Pharmaceuticals, Inc. Registration Statement on Form S-3 Filed June 20, 2025 File No. 333-288205 Dear Jonathan Javitt: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Jason Drory at 202-551-8342 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc:Jack Kennedy
Show Raw Text
June 24, 2025
Jonathan Javitt
Chairman and Interim Chief Executive Officer
NRX Pharmaceuticals, Inc.
1201 Orange Street, Suite 600
Wilmington, DE 19801
Re:NRX Pharmaceuticals, Inc.
Registration Statement on Form S-3
Filed June 20, 2025
File No. 333-288205
Dear Jonathan Javitt:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Jason Drory at 202-551-8342 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:Jack Kennedy